Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate Safety Study in Lennox-Gastaut Syndrome
NCT04062981Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- May 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of carisbamate in Lennox-Gastaut syndrome (LGS) (4 cohorts), sponsored by SK Life Science, Inc. Primary endpoints: Seizure Frequency up to 20 months, Concomitant medication up to 20 months and 2 more. Started May 2019; status: completed.
02
Drugs
carisbamate
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT04062981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062981.